Description: Organovo Holdings, Inc. develops three-dimensional (3D) bioprinting technology for creating functional human tissues on demand for research and medical applications. The company's 3D NovoGen bioprinting technology works across various tissue and cell types, and allows for the placement of cells in desired pattern. It offers NovoGen MMX Bioprinter, a commercial hardware and software bioprinter platform to create tissues for bioprinting research and development. The company was founded in 2007 and is based in San Diego, California.
Home Page: www.organovo.com
ONVO Technical Analysis
11555 Sorrento Valley Road
Solana Beach,
CA
92121
United States
Phone:
858 224 1000
Officers
| Name | Title |
|---|---|
| Mr. Keith E. Murphy | Exec. Chairman |
| Dr. Jeffrey N. Miner | Chief Scientific Officer |
| Mr. Thomas Einar Jurgensen J.D., MS | Gen. Counsel & Corp. Sec. |
| Ms. Vaidehi Joshi | Director of Discovery Biology & Director |
| Mr. Thomas P. Hess CPA, MBA | Pres & CFO |
| Dr. Curtis M. Tyree Ph.D. | Sr. VP of Strategy & Bus. Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6063 |
| Price-to-Sales TTM: | 9.836 |
| IPO Date: | 2012-02-14 |
| Fiscal Year End: | March |
| Full Time Employees: | 20 |